Navigation Links
New Data Shows FusionHealth Sleep Apnea Therapy Reaches Industry-High Results
Date:7/24/2017

A new report released today by FusionHealth, the first comprehensive sleep management solution focused on delivering end-to-end sleep health care at scale, indicates record-breaking adherence results for the company’s obstructive sleep apnea (OSA) program.

Recent literature shows that adherence rates for positive airway pressure (PAP) therapy, the most widely utilized treatment for OSA, typically range between 40 to 60 percent. Today, FusionHealth reported that, across approximately 4,000 users over a 5 year period, 91 percent of participants remained actively engaged in PAP therapy, with an average use of 6.7 days per week at a rate of 6.5 hours per night. These statistics far exceed all regulatory requirements and current clinical practice standards.

In addition, FusionHealth reports that the average participant’s Apnea–Hypopnea Index (AHI), which measures the frequency of sleep-disrupting respiratory events per hour, dropped from a pre-treatment average of 43 per hour (considered severe) to an on-treatment average of 1.5 per hour (considered normal). Furthermore, given that 90 percent of FusionHealth participants remain in therapy for multiple years, not only is healthy sleep restored, but risk for sleep-related chronic comorbidities like obesity, hypertension and cardiovascular disease is reduced.

Lastly, as determined by a well-known clinically-validated quality of life assessment, after the first 90 days of treatment FusionHealth participants experienced a 19 percent improvement in mental health, a 14 percent improvement in physical health, a 25 percent increase in vitality and a 38 percent improvement in their general health and well-being. While participants have experienced individual results, their employers are also seeing direct financial benefits such as a 20 percent savings year-over-year in healthcare costs.

“Treatment for disorders such as obstructive sleep apnea are only effective when they are used,” said Dr. Jeffrey Durmer, co-founder and chief medical officer of FusionHealth. “Unfortunately, a lack of adherence to traditional treatments like PAP therapy is a common problem. As a result, patients not only continue to suffer from poor sleep, but a host of other health issues related to their untreated OSA. That is why the advances made by FusionHealth in this space are so important – not only are more patients given access to treatment, but they are twice as likely to continue their vital therapy under our model.”

ABOUT FUSIONHEALTH
FusionHealth, headquartered in Atlanta, is a sleep health technology company that provides employers and healthcare systems with population-based solutions to address the central problem of poor sleep health. Partnering with FusionHealth, businesses reduce their healthcare spend, improve safety, increase productivity and improve the overall well-being of their workforce. For more information, visit http://www.fusionhealth.com.

Read the full story at http://www.prweb.com/releases/fusionhealth/dr-jeffrey-durmer/prweb14533384.htm.


'/>"/>
Source: PRWeb
Copyright©2017 Vocus, Inc.
All rights reserved


Related medicine news :

1. New Poll Shows CalUniversity and Other Accredited Online Colleges Best Value for Education
2. Prosthetic hands viewed as eerie by the public new study shows
3. 4leafcity.com Shows Its New Men’s Tweed Coat Designs
4. BUSM/BMC study shows decrease in sepsis mortality rates
5. Impulsivity, rewards and Ritalin: Monkey study shows tighter link
6. "Get Rid of Cold Sores Fast" Review Shows How to Overcome Cold Sores in 12 Hours
7. Nanotech researchers 2-step method shows promise in fighting pancreatic cancer
8. Drug shows early promise in treating seizures
9. Depression in pregnancy: New study shows preferences for therapy over medication
10. New study shows spironolactone reduces heart failure hospitalizations, but not mortality
11. Advanced CT imaging proves as accurate as invasive tests to assess heart blockages, study shows
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/14/2019)... ... May 14, 2019 , ... Relatient, Inc., a ... eRegistration and Check-In solution , a new product launched to reduce patient wait ... on Relatient’s Patient Engagement platform introducing earlier touch points on the ...
(Date:5/14/2019)... ... May 14, 2019 , ... A coalition ... the world’s biggest health issues – ‘big data’. At a news conference today, ... Research Centre), Stanford University and Southern Methodist University (SMU) announced the U.S. launch ...
(Date:5/14/2019)... ... May 14, 2019 , ... Forty-two billion dollars – just ... according to market analysis company Orbis Research. “Treatments certainly can help,” notes Angie ... PC , “but for our skin, there’s free super-potent anti-aging care available: It’s ...
(Date:5/14/2019)... ... May 14, 2019 , ... ChoiceSpine ... clearance from the U.S. Food and Drug Administration (FDA) to market TIGER SHARK ... a two-screw configuration, for use together or separately in cervical spinal fusion procedures. ...
(Date:5/14/2019)... YORK (PRWEB) , ... May 14, 2019 , ... Dr. ... for 20 years. Recently he acquired the FX 635 cold laser therapy device, becoming ... working on integrating this cutting edge laser with multiple FDA clearances for treating pain ...
Breaking Medicine News(10 mins):
(Date:5/16/2019)... ... 16, 2019 , ... Actuate Therapeutics, Inc., a clinical stage biopharmaceutical company, today ... Series B is led by Kairos Ventures, with DEFTA Partners, Tech Coast Angels, and ... to expand the company’s ongoing Phase 1 / 2 clinical trial and fund development ...
(Date:5/16/2019)... , ... May 16, 2019 , ... ... and Dr. Peter D. Caie, Senior Research Fellow at St. Andrew University, UK ... EDT (2pm BST/UK) to learn about a deep learning based image analysis solution ...
(Date:5/15/2019)... ... May 15, 2019 , ... E.M.M.A. ... compliance services for the Medical Device industry, will be participating in a panel ... growing digital device field. Also, EMMA International will be delivering a course on ...
Breaking Medicine Technology: